


Do GLP-1 users have unmet behavioral needs?

Many users of GLP-1 (glucagon-like peptide 1) drugs for weight loss have had successful health outcomes in treating chronic conditions but still have unmet behavioral health needs.

To better understand consumer need for behavioral health support alongside GLP-1 usage, Evernorth partnered with Marc Research to survey 300 GLP-1 users with diabetes, cardiovascular disease or challenges with weight management.



For most GLP-1 users, taking these drugs has had a positive impact on their overall health



However, many users face stigma or shame because of their weight




Demand for behavioral health services is high

- 75%** are interested in behavioral health support
- 63%** believe that they will achieve better health outcomes when receiving behavioral health support alongside GLP-1 use

But few are engaging in additional support:

- 17%** of users are accessing behavioral health/talk therapy
- 39%** do not participate in a broader, whole-person health program


The greatest behavioral health needs include:



Different users struggle with different challenges

- Those with weight issues** are more likely to have depression and anxiety
- Younger generations** (age 18-34) are more prone to mental health issues than older ones (35+)
- Women** are more prone to develop depression, stress and anxiety
- Men** are more likely to report struggles with alcohol and drugs

Adherence and combined therapies impact behavioral health over time



We're changing behavioral care for the better

Find out more about how we push boundaries, question the norms and create better experiences for behavioral health.

[LEARN MORE](#)

Contact: businessdevelopment@evernorth.com

Visit: www.evernorth.com/our-solutions/behavioral-health